Charles Kent Osborne

Charles Kent Osborne's AcademicInfluence.com Rankings

Biology

#9555

World Rank

#12773

Historical Rank

Molecular Biology

#1325

World Rank

#1352

Historical Rank

biology Degrees

Download Badge

Biology

Charles Kent Osborne's Degrees

PhD Molecular Biology Stanford University
Bachelors Biochemistry University of California, Berkeley

Why Is Charles Kent Osborne Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Charles Kent Osborne's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. (2008) (1796)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. (2010) (1260)
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. (1993) (807)
The value of estrogen and progesterone receptors in the treatment of breast cancer (1980) (756)
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. (2003) (720)
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu (1992) (643)
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. (2005) (482)
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. (1992) (477)
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. (2005) (464)
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. (1985) (443)
Steroid hormone receptors in breast cancer management (2004) (419)
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. (1994) (413)
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. (1984) (383)
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. (1995) (379)
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. (1987) (377)
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. (1998) (364)
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action (2004) (361)
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. (1989) (361)
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. (1999) (337)
Aberrant Subcellular Localization of BRCA1 in Breast Cancer (1995) (336)
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. (1995) (331)
Tamoxifen in the treatment of breast cancer. (1998) (317)
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. (1983) (306)
Significance of axillary lymph node metastasis in primary breast cancer. (1999) (279)
The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. (2015) (279)
Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. (1989) (272)
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer (2004) (268)
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. (1999) (267)
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. (1991) (263)
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. (2008) (257)
Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. (1989) (251)
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. (1993) (251)
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. (1976) (245)
Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells (1988) (245)
Epidermal growth factor stimulation of human breast cancer cells in culture. (1980) (244)
Location of BRCA1 in Human Breast and Ovarian Cancer Cells (1996) (240)
Histologic progression in non-Hodgkin's lymphoma. (1982) (238)
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. (1999) (231)
Time-dependence of hazard ratios for prognostic factors in primary breast cancer (2004) (225)
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial (2009) (224)
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. (2000) (220)
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. (2013) (219)
Binding of CtIP to the BRCT Repeats of BRCA1 Involved in the Transcription Regulation of p21 Is Disrupted Upon DNA Damage* (1999) (210)
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. (1999) (205)
Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. (1987) (203)
Multiple estrogen receptor assays in human breast cancer. (1983) (194)
Biological differences among MCF-7 human breast cancer cell lines from different laboratories (2005) (190)
Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions* (2001) (166)
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. (1997) (164)
Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. (1978) (160)
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. (2001) (158)
Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. (1988) (157)
An autopsy study of histologic progression in non‐Hodgkin's lymphomas 192 cases from the national cancer institute (1983) (156)
Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. (1992) (153)
Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. (1990) (148)
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen (2004) (144)
Tamoxifen resistance in breast cancer. (1993) (143)
Telomerase activity and survival of patients with node-positive breast cancer. (1997) (142)
bcl‐2 and apoptosis in lymph node positive breast carcinoma (1998) (136)
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth (2002) (134)
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. (1989) (127)
Tamoxifen in premenopausal patients with metastatic breast cancer: a review. (1991) (121)
Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. (1992) (119)
Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. (1984) (117)
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. (1996) (116)
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. (1983) (116)
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. (1992) (113)
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. (1995) (109)
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. (2000) (106)
Regulation of breast cancer growth by insulin-like growth factors (1990) (104)
In vitro model systems for the study of hormone-dependent human breast cancer. (1977) (104)
Mechanisms of tamoxifen resistance (2004) (102)
Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. (1988) (97)
Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. (2001) (95)
Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. (1992) (91)
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth (2004) (87)
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. (2004) (87)
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. (2003) (79)
Heat shock proteins and drug resistance (2004) (79)
Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. (1991) (74)
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. (1998) (73)
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. (2006) (72)
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer (2001) (66)
Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. (1980) (66)
Breast cancer mortality and diet in the United States. (1979) (65)
Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. (1979) (64)
Steroid hormone receptors in the management of human breast cancer. (1980) (64)
Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells. (1981) (63)
Prognostic factors for breast cancer: have they met their promise? (1992) (63)
Oestrogen receptors and breast cancer (1997) (61)
Steroid hormone receptors and carcinoma of the breast. (1982) (59)
Antitumor activity and murine pharmacokinetics of parenteral acronycine. (1989) (56)
Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. (2006) (54)
Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. (1997) (54)
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. (1997) (51)
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. (2009) (50)
Molecular genetic studies of early breast cancer evolution (2004) (50)
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. (1994) (49)
Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). (1998) (47)
Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism (1993) (46)
Prognostic factors in breast cancer. (1989) (45)
Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. (1990) (45)
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. (2000) (45)
Cytological evaluation of biological prognostic markers from primary breast carcinomas (1997) (44)
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. (1999) (43)
Prognostic factors in breast cancer. (1992) (43)
Extranodal presentation of non‐Hodgkin's lymphomas in the testis (1976) (41)
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies (1995) (40)
Perturbation by insulin of human breast cancer cell cycle kinetics. (1984) (40)
Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. (1991) (38)
Low SAFB levels are associated with worse outcome in breast cancer patients (2010) (38)
Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. (2002) (37)
Insights into the role of progesterone receptors in breast cancer. (2005) (37)
Response: Location of BRCA1 in Human Breast and Ovarian Cancer Cells (1996) (36)
Hormone receptors in primary and advanced breast cancer. (1980) (36)
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. (2005) (34)
Immunohistochemical studies of early breast cancer evolution (2004) (32)
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. (1983) (32)
Heterogeneity in hormone receptor status in primary and metastatic breast cancer. (1985) (32)
Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient (2011) (30)
Targeting the EGF receptor in breast cancer treatment (2004) (30)
Current use of steroid hormone receptor assays in the treatment of breast cancer. (1978) (29)
Autocrine and paracrine growth regulation of breast cancer: Clinical implications (2005) (28)
Effects of estrogens and antiestrogens on cell proliferation: implications for the treatment of breast cancer. (1988) (28)
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. (1988) (27)
Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. (1987) (25)
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy (2019) (25)
Human Breast Cancer in Tissue Culture: The Effects of Hormones (1978) (24)
Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. (1995) (23)
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). (1992) (23)
The management of clinically localized prostate cancer. National Institutes of Health Consensus Development Conference, June 15-17, 1987. (1987) (22)
Combined chemo-hormonal therapy in breast cancer: A hypothesis (2005) (19)
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. (1992) (19)
DNA flow cytometry in early breast cancer: a step in the right direction. (1989) (18)
Prognostic factors: Rationale and methods of analysis and integration (2004) (18)
The use of steroïd hormone receptors in the treatment of human breast cancer: a review. (1979) (17)
Circulating tumor DNA--ready for prime time? (2013) (17)
A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). (2012) (16)
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. (2012) (16)
Morphologic and Immunophenotypic Markers as Surrogate Endpoints of Tamoxifen Effect for Prevention of Breast Cancer (2005) (15)
Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration (2004) (15)
Pure Antiestrogens The Most Important Advance in the Endocrine Therapy of Breast Cancer since 1896? a (1996) (15)
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. (2003) (15)
Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis. (1981) (15)
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (A South West Oncology Group Study) (2004) (14)
Modern approaches to the treatment of breast cancer. (1980) (14)
Diseases of the breast: Fifth edition (2014) (14)
Bisantrene, an active drug in patients with advanced breast cancer. (1984) (13)
Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. (1994) (13)
Insulin stimulation of fatty acid synthesis in human breast cancer cells. (1977) (12)
Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study (1998) (12)
Adjuvant therapy in node-negative breast cancer (1989) (11)
The use of restriction fragment polymorphisms to identify the cell line MCF-7 (2005) (10)
Endocrine Therapies in Breast and Prostate Cancer (2011) (10)
The role of growth factors in breast cancer (1988) (9)
Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. (1989) (8)
Urokinase-type receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies (1994) (8)
Estrogen Receptor and Prognosis in Breast Cancer (1981) (8)
Endocrine therapy of human breast cancer grown in nude mice (1987) (8)
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. (2005) (7)
Tamoxifen metabolism as a mechanism for resistance (1995) (7)
Cells Inhibitor of Estrogen Receptor-negative Human Breast Cancer : Potential Autocrine Growth β Transforming Growth Factor (2006) (7)
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. (2003) (6)
Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF). (1996) (6)
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. (2001) (5)
Therapy for cancer of the breast. Current status of steroid hormone receptors. (1979) (5)
Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay (2005) (5)
Cell proliferative indices and DNA content as prognostic factors in primary breast cancer. (1989) (5)
Anaphylactoid reactions associated with bisantrene infusions (1983) (5)
Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model (1988) (5)
Evaluation of patients for metastasis prior to primary therapy (2014) (5)
Athymic nude mouse model for the study of new antioestrogens in breast cancer (1996) (5)
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer (1991) (4)
Bisantrene, biological and clinical effects. (1984) (4)
Antitumor Activity and Murine Pharmacokinetics of Parenteral Acronycine 1 (2006) (3)
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium ‘Breast Cancer – the Development and Validation of New Therapeutics’ (2005) (3)
Dose intensity as a therapeutic strategy in breast cancer (1991) (3)
Rapid identification of transfected plasmid expression vectors in cells by PCR. (1991) (3)
8 Steroid Receptors in Relation to Response (1988) (3)
Resistance to endocrine therapy A panel discussion (2005) (3)
Abstract 319: Role of GPR110 on tumorigenesis and metastasis in HER2+ breast cancer in the context of anti-HER2 drug resistance (2016) (3)
William Leo McGuire, MD 1937–1992 (1992) (3)
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer (2022) (2)
BRCA1 in clinical breast cancer. (1998) (2)
Diseases of the Breast 4/e (2009) (2)
Characterization of insulin regulation of lipid synthesis in MCF-7 human breast cancer cells (1983) (2)
Adjuvant treatment of node-negative breast cancer. (1989) (2)
Current trials and future directions of the Southwest Oncology Group Breast Cancer Committee. (1994) (2)
Pain control in breast cancer (2005) (2)
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. (1991) (2)
Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition. (1982) (2)
ER/HER2-Positive Metastatic Breast Cancer Patient Optimizing Chemotherapy-Free Survival for the (2011) (2)
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2003) (2)
Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer (2004) (1)
Overexpression Causes Growth Arrest and Multinuclearity and Is Associated with Aneuploidy in Human Breast Cancer 1 (2000) (1)
SERMs and Breast Cancer Prevention (2002) (1)
Insulin receptors in human breast cancer: relationship of binding, degradation and biological activity (1976) (1)
Non-nuclear human estrogen receptor-alpha 36 (hERα-36) is expressed in ER, PR, and Her2 positive or negative breast cancer patients as well as cell lines, and physically interacts with Her2 (2008) (1)
Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52 (2019) (1)
Translational research in the San Antonio breast cancer SPORE (2004) (1)
Preface to the fifth edition (2014) (0)
The Small Heat Shock Protein hsp27 Is Correlated with Growth and Drug Resistance in Human Breast Cancer Cell Lines 1 (2007) (0)
Interview: The targeted therapy era of breast cancer (2012) (0)
Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody against the Type I Somatomedin Receptor1 (2006) (0)
Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting. (2011) (0)
A New Concept of Breast Cancer Growth Regulation and its Potential Clinical Applications (1989) (0)
SABCS: Research From This Year's Conference (2011) (0)
Adjuvant endocrine treatment tailoring in 2006 — dream or reality? (2006) (0)
Receptors - Their prognostic and predictive value (2000) (0)
Adjuvant therapy for breast cancer. (1988) (0)
Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer (1989) (0)
Abstract P3-06-12: Autophagy-mediated survival mechanism to c-Src inhibitor therapy in triple negative breast cancer (2020) (0)
Tumor C haracteristics a nd C linical O utcome o f T ubular and M ucinous B reast C arcinomas (1999) (0)
Spreading the word, but not too thinly (2004) (0)
Epidermal Growth Factor Stimulation of Human Breast Cancer Cells in Culture 1 (2006) (0)
Hematopoietic growth factors in breast cancer — Overview (1991) (0)
Immunoreactive a. Transforming Growth Factor Activity in Effusions from Cancer Patients as a Marker of Tumor Burden and Patient Prognosis1 (2006) (0)
Toremifene — panel discussion and summary (1990) (0)
Polypeptide growth factors: their potential value in the management of breast cancer patients. (1992) (0)
Growth Factor-mediated Signaling and Growth-negative MCF-7 Cells Restores both Estrogen and Insulin-like α in Estrogen Receptor α Re-expression of Estrogen Receptor Updated (2001) (0)
The MAPK inhibitor, MKP3, is an estrogen receptor α coactivator associated with tamoxifen resistance (2005) (0)
Abstract P6-11-01: A broad spectrum therapeutic strategy for TNBC revealed by a new pathway that coordinates oncogenic RTKs (2015) (0)
The hypothesis of hormonal manipulation of tumor cells in combination with chemotherapy (1986) (0)
Potential and problems with growth of breast cancer in a human tumor cloning system (2005) (0)
Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer (2020) (0)
Transforming Growth Factor ÃŸ:Potential Autocrine Growth Inhibitor of Estrogen Receptor-negative Human Breast Cancer Cells1 (2006) (0)
Abstract 2296: Identification of novel nuclear receptor targets in estrogen receptor negative breast cancer (2011) (0)
Significance o f A xillary L ymph N ode M etastasis in P rimary B reast C ancer (1999) (0)
151 Effects of antiestrogens and estrogens on proliferation of human breast cancer cells; in vitro and in vivo models. (1983) (0)
Megestrol acetate in breast cancer — A panel discussion (1989) (0)
Insulin stimulates acetyl Co A carboxylase in human breast cancer cells: Possible mechanism of somatotrophic effect of insulin (1978) (0)
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer (2023) (0)
Aromatase inhibitors in the treatment of advanced breast cancer. Introduction. (1996) (0)
Human Breast Cancer Cell Cycle Synchronization by Estrogens and Antiestrogens in Culture 1 (2006) (0)
Antitumor Activity and Murine Pharmacokinetics (2006) (0)
Clinical Implications of Tamoxifen's Mechanism of Action (1988) (0)
Hormone receptors in the management of breast cancer. (1984) (0)
Adjuvant chemotherapy (1986) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Charles Kent Osborne?

Charles Kent Osborne is affiliated with the following schools: